Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C.-H. Koehne, H. J. Kolb, C. Schmid & H. M. Schmetzer. (2020) Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease. Immunological Investigations 49:4, pages 365-385.
Read now
Read now
Teilo H. Schaller, Kristen A. Batich, Carter M. Suryadevara, Rupen Desai & John H. Sampson. (2017) Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Review of Clinical Immunology 13:11, pages 1049-1060.
Read now
Read now
Rajesh K Sharma, Zinal S Chheda, Venkatakrishna R Jala & Bodduluri Haribabu. (2015) Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. Expert Review of Vaccines 14:4, pages 537-549.
Read now
Read now
Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:4.
Read now
Read now
Gautier Stoll, David Enot, Bernhard Mlecnik, Jérôme Galon, Laurence Zitvogel & Guido Kroemer. (2014) Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology 3:3.
Read now
Read now
Articles from other publishers (23)
Jack Y. Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Erica Browning, H. Kim Lyerly, David A. Canton, Daniel Fisher, Adil Daud, Alain Algazi, Joseph Skitzki & Christopher G. Twitty. (2022) Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics 25, pages 174-188.
Crossref
Crossref
Alain E. Andrea, Andrada Chiron, Sarah Mallah, Stéphanie Bessoles, Guillaume Sarrabayrouse & Salima Hacein-Bey-Abina. (2022) Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Frontiers in Immunology 13.
Crossref
Crossref
Nobuyuki Ishikura, Masamichi Sugimoto, Keigo Yorozu, Mitsue Kurasawa & Osamu Kondoh. (2021)
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1
low
and immune desert‑like mouse tumors
. Oncology Reports 47:2.
Crossref
Crossref
Saeed Asiry, Gina Kim, Panagiota S. Filippou, Luis Rivera Sanchez, David Entenberg, Douglas K. Marks, Maja H. Oktay & George S. Karagiannis. (2021) The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. Frontiers in Immunology 12.
Crossref
Crossref
Gizem Duru, Marjolein van Egmond & Niels Heemskerk. (2020) A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Min-Wei Yang, Ling-Ye Tao, Yong-Sheng Jiang, Jian-Yu Yang, Yan-Miao Huo, De-Jun Liu, Jiao Li, Xue-Liang Fu, Ruizhe He, Chaoyi Lin, Wei Liu, Jun-Feng Zhang, Rong Hua, Qing Li, Shu-Heng Jiang, Li-Peng Hu, Guang-Ang Tian, Xiao-Xin Zhang, Ningning Niu, Ping Lu, Juanjuan Shi, Gary G. Xiao, Li-Wei Wang, Jing Xue, Zhi-Gang Zhang & Yong-Wei Sun. (2020) Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Cancer Research 80:10, pages 1991-2003.
Crossref
Crossref
Cathy Eng, Marwan Fakih, Manik Amin, Van Morris, Howard S. Hochster, Patrick M. Boland & Hope Uronis. (2020) A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget 11:15, pages 1334-1343.
Crossref
Crossref
Imran G. House, Peter Savas, Junyun Lai, Amanda X.Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy & Paul A. Beavis. (2020) Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research 26:2, pages 487-504.
Crossref
Crossref
Hui-Feng Gao, Chien-Shan Cheng, Jian Tang, Ye Li, Hao Chen, Zhi-Qiang Meng, Zhen Chen & Lian-Yu Chen. (2020) CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Aging 12:1, pages 502-517.
Crossref
Crossref
Aleksei Titov, Aygul Valiullina, Ekaterina Zmievskaya, Ekaterina Zaikova, Alexey Petukhov, Regina Miftakhova, Emil Bulatov & Albert Rizvanov. (2020) Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers 12:1, pages 125.
Crossref
Crossref
Marco Tucci, Anna Passarelli, Francesco Mannavola, Claudia Felici, Luigia Stefania Stucci, Mauro Cives & Francesco Silvestris. (2019) Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology 9.
Crossref
Crossref
Lynn G. Feun, Ying‐Ying Li, Chunjing Wu, Medhi Wangpaichitr, Patricia D. Jones, Stephen P. Richman, Beatrice Madrazo, Deukwoo Kwon, Monica Garcia‐Buitrago, Paul Martin, Peter J. Hosein & Niramol Savaraj. (2019) Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer 125:20, pages 3603-3614.
Crossref
Crossref
Jake S. O’Donnell, Michele W. L. Teng & Mark J. Smyth. (2018) Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology 16:3, pages 151-167.
Crossref
Crossref
Chien-Chun Steven Pai, John T. Huang, Xiaoqing Lu, Donald M. Simons, Chanhyuk Park, Anthony Chang, Whitney Tamaki, Eric Liu, Kole T. Roybal, Jane Seagal, Mingyi Chen, Katsunobu Hagihara, Xiao X. Wei, Michel DuPage, Serena S. Kwek, David Y. Oh, Adil Daud, Katy K. Tsai, Clint Wu, Li Zhang, Marcella Fasso, Ravi Sachidanandam, Anitha Jayaprakash, Ingrid Lin, Amy-Jo Casbon, Gillian A. Kinsbury & Lawrence Fong. (2019) Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity 50:2, pages 477-492.e8.
Crossref
Crossref
Zhijuan Qiu, Camille Khairallah & Brian Sheridan. (2018) Listeria Monocytogenes: A Model Pathogen Continues to Refine Our Knowledge of the CD8 T Cell Response. Pathogens 7:2, pages 55.
Crossref
Crossref
Brett A. Miles, Bradley J. Monk & Howard P. Safran. (2017) Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecologic Oncology Research and Practice 4:1.
Crossref
Crossref
Anna H. Turaj, Khiyam Hussain, Kerry L. Cox, Matthew J.J. Rose-Zerilli, James Testa, Lekh N. Dahal, H.T. Claude Chan, Sonya James, Vikki L. Field, Matthew J. Carter, Hyung J. Kim, Jonathan J. West, Lawrence J. Thomas, Li-Zhen He, Tibor Keler, Peter W.M. Johnson, Aymen Al-Shamkhani, Stephen M. Thirdborough, Stephen A. Beers, Mark S. Cragg, Martin J. Glennie & Sean H. Lim. (2017) Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell 32:6, pages 777-791.e6.
Crossref
Crossref
Monica Gordon-Alonso, Thibault Hirsch, Claude Wildmann & Pierre van der Bruggen. (2017) Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nature Communications 8:1.
Crossref
Crossref
Melek M.E. Sunay, Jeremy B. Foote, James M. Leatherman, Justin P. Edwards, Todd D. Armstrong, Christopher J. Nirschl, Jessica Hicks & Leisha A. Emens. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. International Immunopharmacology 46, pages 112-123.
Crossref
Crossref
Kristin G. Anderson, Ingunn M. Stromnes & Philip D. Greenberg. (2017) Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell 31:3, pages 311-325.
Crossref
Crossref
Chanyu Yue, Jun Xu, Marc Daryl Tan Estioko, Kevin P. Kotredes, Yolanda Lopez-Otalora, Brendan A. Hilliard, Darren P. Baker, Stefania Gallucci & Ana M. Gamero. (2015) Host STAT2/type I interferon axis controls tumor growth. International Journal of Cancer 136:1, pages 117-126.
Crossref
Crossref
Clare Y. Slaney, Michael H. Kershaw & Phillip K. Darcy. (2014) Trafficking of T Cells into Tumors. Cancer Research 74:24, pages 7168-7174.
Crossref
Crossref
Laurence M. Wood & Yvonne Paterson. (2014) Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Frontiers in Cellular and Infection Microbiology 4.
Crossref
Crossref